Pro-inflammatory mediator and cancer-associated chemokine CXCL8 as a prognostic indicator of tumor aggressiveness, angiogenesis, and disease progression with focus on therapeutic implications and recurrence monitoring

Oral Oncology Reports Pub Date : 2025-02-05 DOI:10.1016/j.oor.2025.100723

Hema Shree K , Gayathri R , Vishnu Priya Veeraraghavan , Selvaraj J , Pratibha Ramani

{"title":"Pro-inflammatory mediator and cancer-associated chemokine CXCL8 as a prognostic indicator of tumor aggressiveness, angiogenesis, and disease progression with focus on therapeutic implications and recurrence monitoring","authors":"Hema Shree K , Gayathri R , Vishnu Priya Veeraraghavan , Selvaraj J , Pratibha Ramani","doi":"10.1016/j.oor.2025.100723","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Oral Squamous Cell Carcinoma (OSCC) is a prevalent malignancy characterized by high morbidity and mortality. Chronic inflammation within the tumor microenvironment plays a pivotal role in OSCC progression, with CXCL8 or interleukin-8 (IL-8) emerging as a significant cytokine implicated in various pro-tumorigenic processes. IL-8 promotes angiogenesis, immune evasion, and cancer cell stemness, contributing to tumor aggression and resistance to therapy. Understanding longitudinal changes in IL-8 expression provides insights into OSCC progression and treatment responses, potentially guiding personalized therapeutic strategies.</div></div><div><h3>Objectives</h3><div>To investigate longitudinal trends in IL-8 expression among OSCC patients. To assess correlations between IL-8 levels and disease progression, treatment outcomes, and patient survival. To evaluate IL-8's prognostic value as a biomarker and its potential as a therapeutic target.</div></div><div><h3>Methods</h3><div>A prospective longitudinal study enrolled 75 OSCC patients divided into pre-treatment, post-treatment, and follow-up groups. Saliva samples were collected, and IL-8 expression levels were quantified using RT-PCR and ELISA. Temporal trends in IL-8 expression and associations with clinical outcomes were analyzed using mixed-effects models and Kaplan-Meier survival analysis.</div></div><div><h3>Results</h3><div>Significant elevation of IL-8 levels was observed in OSCC patients compared to controls. IL-8 levels decreased post-treatment but remained elevated compared to controls, with higher levels correlating with advanced tumor stages and poorer differentiation. Kaplan-Meier analysis demonstrated reduced survival probabilities in patients with persistently high IL-8 expression.</div></div><div><h3>Conclusions</h3><div>Longitudinal monitoring of IL-8 expression offers valuable insights into OSCC pathogenesis and treatment response. IL-8's role as a prognostic biomarker and therapeutic target warrants further exploration to enhance disease management and patient outcomes.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":"13 ","pages":"Article 100723"},"PeriodicalIF":0.0000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772906025000111","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Oral Squamous Cell Carcinoma (OSCC) is a prevalent malignancy characterized by high morbidity and mortality. Chronic inflammation within the tumor microenvironment plays a pivotal role in OSCC progression, with CXCL8 or interleukin-8 (IL-8) emerging as a significant cytokine implicated in various pro-tumorigenic processes. IL-8 promotes angiogenesis, immune evasion, and cancer cell stemness, contributing to tumor aggression and resistance to therapy. Understanding longitudinal changes in IL-8 expression provides insights into OSCC progression and treatment responses, potentially guiding personalized therapeutic strategies.

Objectives

To investigate longitudinal trends in IL-8 expression among OSCC patients. To assess correlations between IL-8 levels and disease progression, treatment outcomes, and patient survival. To evaluate IL-8's prognostic value as a biomarker and its potential as a therapeutic target.

Methods

A prospective longitudinal study enrolled 75 OSCC patients divided into pre-treatment, post-treatment, and follow-up groups. Saliva samples were collected, and IL-8 expression levels were quantified using RT-PCR and ELISA. Temporal trends in IL-8 expression and associations with clinical outcomes were analyzed using mixed-effects models and Kaplan-Meier survival analysis.

Results

Significant elevation of IL-8 levels was observed in OSCC patients compared to controls. IL-8 levels decreased post-treatment but remained elevated compared to controls, with higher levels correlating with advanced tumor stages and poorer differentiation. Kaplan-Meier analysis demonstrated reduced survival probabilities in patients with persistently high IL-8 expression.

Conclusions

Longitudinal monitoring of IL-8 expression offers valuable insights into OSCC pathogenesis and treatment response. IL-8's role as a prognostic biomarker and therapeutic target warrants further exploration to enhance disease management and patient outcomes.

查看原文